100 mg clindamycin /800 mg ketoconazole vaginal ovule + 100 mg tetracycline hydrochloride /50 mg amphotericin B cream
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Vaginosis, Bacterial
Conditions
Vaginosis, Bacterial, Candidiasis, Vulvovaginal
Trial Timeline
May 1, 2010 → Jan 1, 2011
NCT ID
NCT01293643About 100 mg clindamycin /800 mg ketoconazole vaginal ovule + 100 mg tetracycline hydrochloride /50 mg amphotericin B cream
100 mg clindamycin /800 mg ketoconazole vaginal ovule + 100 mg tetracycline hydrochloride /50 mg amphotericin B cream is a phase 3 stage product being developed by Merck for Vaginosis, Bacterial. The current trial status is completed. This product is registered under clinical trial identifier NCT01293643. Target conditions include Vaginosis, Bacterial, Candidiasis, Vulvovaginal.
What happened to similar drugs?
4 of 4 similar drugs in Vaginosis, Bacterial were approved
Approved (4) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01293643 | Phase 3 | Completed |
Competing Products
5 competing products in Vaginosis, Bacterial
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Colposeptine + Metronidazole | Merck | Approved | 35 |
| Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring | Merck | Approved | 39 |
| metronidazole and azithromycin | Pfizer | Approved | 43 |
| Lactoserum (Dermacyd Femina®) | Sanofi | Approved | 43 |
| BNT331 | BioNTech | Phase 1 | 26 |